Related Experiment Videos
Priming effect of orally administered muramyl dipeptide on induction of endogenous tumor necrosis factor
T Okutomi1, H Inagawa, T Nishizawa
1Biotechnology Research Center, Teikyo University, Kanagawa, Japan.
Abstract:
Orally administered muramyl dipeptide (MDP) was found to prime induction of endogenous tumor necrosis factor (TNF) in mice. This priming effect was observed after oral administration of MDP of more than 100 micrograms/mouse; the maximal time interval between oral administration of MDP and i.v. injection of OK-432, a triggering agent for induction of endogenous TNF, was extended over 3-10 h and then decreased after 24 h. Antitumor effect against Meth-A, MH134, and MM46 tumor cells in mice was observed after oral administration of MDP followed by i.v. injection of OK-432. These findings suggest that orally administered MDP can be used as a priming agent for inducing endogenous TNF in cancer patients, and that MDP, a component of enteric bacteria, must have an important role in maintaining homeostasis through activation of macrophages.
Insights
Orally administered muramyl dipeptide (MDP) primes the body to produce tumor necrosis factor (TNF). This priming enhances anti-tumor effects when combined with a triggering agent, suggesting potential cancer therapy applications.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Muramyl dipeptide (MDP) is a component of bacterial cell walls.
- Tumor necrosis factor (TNF) is a key cytokine involved in inflammation and immune responses.
- The role of orally administered MDP in modulating endogenous TNF production is not fully understood.
Purpose of the Study:
- To investigate the effect of orally administered muramyl dipeptide (MDP) on the induction of endogenous tumor necrosis factor (TNF) in mice.
- To evaluate the potential anti-tumor efficacy of MDP-primed TNF induction.
Main Methods:
- Mice were orally administered varying doses of MDP.
- A triggering agent (OK-432) was administered intravenously at different time points after MDP.
- TNF induction levels and anti-tumor effects against specific cancer cell lines (Meth-A, MH134, MM46) were assessed.
Main Results:
- Oral administration of MDP (≥100 µg/mouse) effectively primed TNF induction.
- The optimal priming window was observed between 3-10 hours post-MDP administration.
- Combined MDP priming and OK-432 treatment demonstrated significant anti-tumor effects in mice.
Conclusions:
- Orally administered MDP can serve as a priming agent for endogenous TNF induction.
- This priming enhances anti-tumor activity, suggesting potential therapeutic applications in cancer treatment.
- MDP may play a crucial role in immune homeostasis via macrophage activation.